Glossary : Legal/Privacy : Contact  
 
 

Tangent Reprofiling

Technology

Tangent Reprofiling has a proprietary lab-based technique that uses chemical genomics to explore novel interactions between proteins and small molecule drugs. These discoveries suggest new therapeutic applications for the drugs and hence inform our drug development programmes in a reprofiling strategy.

Product Pipeline

The nature of our screening ensures a wide, varied and rapidly changing product pipeline. At the present time this includes therapeutic applications in oncology, CNS diseases and infectious diseases.

Commercial

Tangent Reprofiling is seeking co-development and licensing partners for its programmes to assist in taking its products to the market. The company is flexible with respect to the type and structure of such agreements and would be prepared to enter into collaborations on both a therapeutic area and individual project basis.

Company History and Corporate Information

In December 2008, PepTcell invested in Tangent Reprofiling Limited in which it currently holds approximately 58%.

Tangent Reprofiling has acquired the intellectual property from a2sp Limited which was a company previously spun out the Department of Chemistry at the University of Warwick.

The employees of a2sp have also moved across to Tangent Reprofiling and Dr Suzanne Dilly has been appointed the CEO of Tangent Reprofiling. Dr Paul Taylor, an associate professor of organic chemistry at the University of Warwick, is a director and consultant to Tangent Reprofiling.

Tangent Reprofiling contact details are as follows:

Dr Suzanne Dilly

Tel: +(44)(0)1869 238 028
Mobile: +(44)(0)7870 110 654
Email: suzanne.dilly@tangentreprofiling.com

Postal Address:

CentralPoint
45 Beech Street
London
EC2Y 8AD
United Kingdom

Company Number: 6704572
 
Related Links
New Uses for Old Drugs
Read more...
 
 
PepTcell Limited Central Point 45 Beech Street London EC2Y 8AD                  Glossary : Legal/Privacy : Contact